Eli Lilly’s obesity drug nears approval in Japan, CEO confirms



Eli Lilly Chair and CEO David Ricks announced on Friday that the company’s popular obesity treatment, Zepbound, will be approved in Japan by mid-2025. Speaking with Nikkei Assia, Ricks confirmed that …
About the author:

Get involved!

Fai trading in gruppo!
L'unica Academy di trading completamente gratuita per gli utenti FpMarkets

Comments

Ancora nessun commento